| 02-19-2008 06:39 PM CET - Science & Education |
|
Trevigen Launches High-Throughput PARP/Apoptosis Assays
Press release from: Trevigen, Inc.
(openPR) - Trevigen launches High-Throughput PARP/Apoptosis Assays ideal for measuring the activity of PARP in 96-well plates. Cell extracts can be obtained using our newly-developed, higher-throughput procedure before, during and after apoptosis induction. During apoptosis, PARP-1 which catalyzes the NAD dependent addition of poly (ADP-ribose) (PAR) onto various cytoplasmic and nuclear proteins, is cleaved from its enzymatically active form (about 116 kDa), to its inactive form (85 kDa). The HT PARP/Apoptosis Assay is an ELISA which semi-quantitatively detects PAR deposited onto immobilized histone proteins (via PARP activity) in a 96-well format.
Trevigen offers two formats of the HT PARP/Apoptosis Assay: Cat#4684-096-K (Colorimetric) and Cat# 4685-096-K (Chemiluminescent). Additional histone-coated strip wells (Cat# 4677-096-P) are available separately. For details, contact Trevigen, at 800-873-8443, info@trevigen.com or visit the website at www.trevigen.com.
Press Contact:
Belinda De Leon
800-873-8443
info@trevigen.com
Trevigen, Inc.
8405 Helgerman Ct.
Gaithersburg, MD 20877
1-800-TREVIGEN
www.trevigen.com
Trevigen is a long standing provider of quality kits and reagents for researchers investigating programmed cell death, DNA damage and repair, cell differentiation and angiogenesis.
Trevigen offers two formats of the HT PARP/Apoptosis Assay: Cat#4684-096-K (Colorimetric) and Cat# 4685-096-K (Chemiluminescent). Additional histone-coated strip wells (Cat# 4677-096-P) are available separately. For details, contact Trevigen, at 800-873-8443, info@trevigen.com or visit the website at www.trevigen.com.
Press Contact:
Belinda De Leon
800-873-8443
info@trevigen.com
Trevigen, Inc.
8405 Helgerman Ct.
Gaithersburg, MD 20877
1-800-TREVIGEN
www.trevigen.com
Trevigen is a long standing provider of quality kits and reagents for researchers investigating programmed cell death, DNA damage and repair, cell differentiation and angiogenesis.
News-ID: 37825
More releases
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.
Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.
© openPR 2012 | Imprint
More Releases from
Trevigen, Inc.
Comments about openPR
I can't but agree to the positive statements about your portal:
easy to use, clear layout, very good search function, and quick editing!
Jens O'Brien, Borgmeier Media Communication
easy to use, clear layout, very good search function, and quick editing!
Jens O'Brien, Borgmeier Media Communication


